Phase II Trial of Pembrolizumab Plus Gemcitabine, Vinorelbine, and Liposomal Doxorubicin as Second-Line Therapy for Relapsed or Refractory Classical Hodgkin Lymphoma.

Alison J. Moskowitz,Gunjan L. Shah,Heiko Schöder,Nivetha Ganesan,Esther Drill,Helen Hancock,Theresa Davey,Leslie Perez,Sunyoung Ryu,Samia Sohail,Alayna Santarosa,Natasha Galasso,Rachel Neuman,Brielle Liotta,William Blouin,Anita Kumar,Oscar B. Lahoud,Connie Lee Batlevi,Paul A. Hamlin,David J. Straus,Ildefonso Rodriguez-Rivera,Colette Owens,Philip Caron,Andrew M. Intlekofer,Audrey Hamilton,Steven M. Horwitz,Lorenzo Falchi,Erel Joffe,William T. Johnson,Christina R. Lee,M. Lia Palomba,Ariela Noy,Matthew J. Matasar,Georgios Pongas,Gilles Salles,Santosha A. Vardhana,Beatriz Wills Sanín,Gottfried von Keudell,Joachim Yahalom,Ahmet Dogan,Andrew D. Zelenetz,Craig H. Moskowitz

Phase II Trial of Pembrolizumab Plus Gemcitabine, Vinorelbine, and Liposomal Doxorubicin as Second-Line Therapy for Relapsed or Refractory Classical Hodgkin Lymphoma.

2021

PURPOSEWe conducted a phase II study evaluating pembrolizumab plus gemcitabine, vinorelbine, and liposomal doxorubicin (pembro-GVD) as second-line therapy for relapsed or refractory (rel/ref) class...

Keywords:

Internal medicine
Vinorelbine
Gemcitabine
Pembrolizumab
Medicine
Phases of clinical research
Liposomal Doxorubicin
Second-line therapy
Gemcitabine/Vinorelbine
Oncology
Refractory

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations